Clinical performance

Diaverum’s patients benefit from standards of care which include a number of clinical performance measures related to dialysis adequacy, nutrition, anaemia management and mineral and bone disorder.

 Clinical performance measures

  Q1 2019 Q1 2018
Single-pool Kt/V ≥ 1.4 (%) 87 85
Weekly treatment time ≥ 720 minutes (%) 95 95
Albumin ≥ 3.5 g/dl (%) 88 88
Haemoglobin 10 - 12 g/dl (%) 66 64
Phosphorus 2.5 - 5.5 mg/dl (%) 73 71
Calcium x Phosphorus product < 55 mg² / dl² (%) 85 84

Kt/V: A measure of dialysis adequacy

Kt/V is the universally recognised measure of the dialysis dose delivered. K refers to the clearance, which is the capacity of the dialyser to clean the blood of urea; t refers to the length of time of the treatment; and V refers to the volume of water within the patient. Most standards recommend a minimum acceptable target for single-pool Kt/V of 1.4 in a thrice-weekly dialysis schedule.

Weekly treatment time: Quantity is quality

Treatment time is an independent indicator of survival in dialysis. The aim is to provide a dialysis treatment time of at least 720 minutes per week to our patients.

Albumin: A measure of nutrition and inflammation

Albumin is the major plasma protein responsible for much of the plasma colloid osmotic pressure, as it cannot pass through the walls of blood vessels.

In dialysis patients, serum albumin is used as a marker of nutrition but also of inflammation. A serum albumin concentration of > 3.5 g/dl is generally defined as adequate, although the target value may depend on the analysis method used.

Haemoglobin: A measure of anaemia management

Haemoglobin is the iron-containing protein in red blood cells that transports oxygen in the body. Haemoglobin is used as a measure of anaemia management. Diaverum aims to ensure patients have a haemoglobin level of between 10 - 12 g/dl, the current target for haemoglobin in dialysis patients according to guidelines.

Phosphorus: A measure of mineral and bone disorder

Phosphorus is, among other things, required for bone formation. Patients with end-stage kidney disease in general have increased serum levels of phosphorus, which may contribute to cardiovascular and soft tissue calcification. The aim is to achieve a serum phosphorus level in the range of 2.5 - 5.5 mg/dl.